Recent developments in immunotoxin therapy

Maria Ana Ghetie; Ellen S. Vitetta

doi:10.1016/0952-7915(94)90073-6

Recent developments in immunotoxin therapy

Maria Ana Ghetie, Ellen S. Vitetta

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.

Original language	English (US)
Pages (from-to)	707-714
Number of pages	8
Journal	Current Opinion in Immunology
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/0952-7915(94)90073-6
State	Published - 1994

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/0952-7915(94)90073-6

Cite this

@article{bf5da3c2d06f4889819cd82c474eb808,

title = "Recent developments in immunotoxin therapy",

abstract = "Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.",

author = "Ghetie, {Maria Ana} and Vitetta, {Ellen S.}",

year = "1994",

doi = "10.1016/0952-7915(94)90073-6",

language = "English (US)",

volume = "6",

pages = "707--714",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Recent developments in immunotoxin therapy

AU - Ghetie, Maria Ana

AU - Vitetta, Ellen S.

PY - 1994

Y1 - 1994

N2 - Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.

AB - Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.

UR - http://www.scopus.com/inward/record.url?scp=0028148350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028148350&partnerID=8YFLogxK

U2 - 10.1016/0952-7915(94)90073-6

DO - 10.1016/0952-7915(94)90073-6

M3 - Article

C2 - 7826525

AN - SCOPUS:0028148350

SN - 0952-7915

VL - 6

SP - 707

EP - 714

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

IS - 5

ER -

Recent developments in immunotoxin therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this